U.S. stock index futures indicated a lower open as investors weighed the possibility of a December rate hike, amid the release of GDP and earnings.» Read More
The Fed turned up the heat around a possible December rate hike, just as the government is about to release a report expected to show sluggish GDP growth.
Jim Cramer says to wait for this group to come in before pouncing on this stock when he gave his take on caller favorite stocks.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
Oct 23- The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's Strensiq, a treatment for a rare kind of metabolic bone disorder. The approval is the first in the United States for a treatment for perinatal, infantile and juvenile-onset hypophosphatasia. The debilitating disorder affects fewer than 200,000 patients in the...
Oct 23- The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's Strensiq, a treatment for a rare kind of metabolic disorder.
As the third-quarter earnings season gets underway, here are some lesser-known plays from some of today's top money managers.
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
Fears of tepid global world took center stage this week once again, sending equity benchmarks across the board in the red this week.
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.
Sept 4- Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.. The FDA, which has granted the drug "breakthrough therapy" status for LAL deficiency in infants, was expected to make its decision by Sept. 8.
NEW YORK, Sept 1- Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving...
NEW YORK, Sept 1- Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for two drugs acquired through the deal, both enzyme-replacement therapies for ultra-rare, life threatening diseases. The treatments are awaiting U.S. approval decisions after receiving...
CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
TIAA-CREF portfolio manager Saira Malik sees opportunity with a likely market correction before a Fed rate hike. Here are her picks.
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.
The next takeout target in biotech? Here are three eligible candidates
Evercore ISI’s Mark Schoenebaum couldn't believe the Alexion and Synageva deal.
Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.